Expression of novel and established stem cell antigens and lineage-related markers on leukemic stem and progenitor cells and comparison with normal BM cells
| Antigen . | CD . | Normal control BM . | AML . | CML . | |||
|---|---|---|---|---|---|---|---|
| CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | ||
| ROBO4 | n.c. | +/− (50) | + (100) | − (5) | −/+ (29) | − (7) | + (85) |
| IL-1RAP | n.c. | −/+ (36) | − (0) | + (79) | + (65) | + (95) | + (77) |
| IL-2RA | CD25 | − (12) | − (8) | + (43) | + (48) | +/− (28) | + (93) |
| DPPIV | CD26 | − (0) | − (0) | −/+ (8) | −/+ (10) | +/− (30) | + (97) |
| Leukosialin | CD43 | + (100) | + (100) | + (100) | + (100) | + (100) | + (100) |
| Pgp-1 | CD44 | + (100) | + (100) | + (98) | + (98) | + (100) | + (100) |
| LCA | CD45 | + (100) | + (100) | + (100) | + (100) | + (100) | + (100) |
| NCAM1 | CD56 | − (8) | − (8) | −/+ (26) | −/+ (18) | +/− (55) | + (91) |
| Thy1 | CD90 | −/+ (8) | + (85) | − (4) | −/+ (13) | +/− (55) | + (91) |
| MXRA4 | CD93 | +/− (75) | +/− (63) | + (81) | + (72) | +/− (71) | + (86) |
| TACTILE | CD96 | − (0) | − (0) | + (51) | + (40) | − (9) | − (0) |
| AC133 | CD133 | + (100) | + (100) | + (86) | + (88) | +/− (72) | + (89) |
| OX40 | CD134 | − (0) | − (0) | − (8) | − (6) | − (0) | − (0) |
| SLAMF1 | CD150 | − (0) | − (0) | − (3) | − (0) | − (0) | − (0) |
| BST1 | CD157 | + (90) | + (90) | + (85) | + (74) | + (100) | + (100) |
| CXCR4 | CD184 | + (68) | + (55) | + (75) | + (72) | + (82) | + (82) |
| E-NPP3 | CD203c | − (0) | − (0) | − (0) | − (0) | − (11) | − (0) |
| MDR1 | CD243 | − (10) | − (0) | − (6) | − (10) | − (3) | − (7) |
| OX40L | CD252 | − (0) | − (0) | − (0) | − (0) | −/+ (33) | −/+ (33) |
| CLL-1 | CD371 | + (100) | − (0) | + (92) | + (68) | + (67) | − (17) |
| Antigen . | CD . | Normal control BM . | AML . | CML . | |||
|---|---|---|---|---|---|---|---|
| CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | CD34+/CD38+ . | CD34+/CD38− . | ||
| ROBO4 | n.c. | +/− (50) | + (100) | − (5) | −/+ (29) | − (7) | + (85) |
| IL-1RAP | n.c. | −/+ (36) | − (0) | + (79) | + (65) | + (95) | + (77) |
| IL-2RA | CD25 | − (12) | − (8) | + (43) | + (48) | +/− (28) | + (93) |
| DPPIV | CD26 | − (0) | − (0) | −/+ (8) | −/+ (10) | +/− (30) | + (97) |
| Leukosialin | CD43 | + (100) | + (100) | + (100) | + (100) | + (100) | + (100) |
| Pgp-1 | CD44 | + (100) | + (100) | + (98) | + (98) | + (100) | + (100) |
| LCA | CD45 | + (100) | + (100) | + (100) | + (100) | + (100) | + (100) |
| NCAM1 | CD56 | − (8) | − (8) | −/+ (26) | −/+ (18) | +/− (55) | + (91) |
| Thy1 | CD90 | −/+ (8) | + (85) | − (4) | −/+ (13) | +/− (55) | + (91) |
| MXRA4 | CD93 | +/− (75) | +/− (63) | + (81) | + (72) | +/− (71) | + (86) |
| TACTILE | CD96 | − (0) | − (0) | + (51) | + (40) | − (9) | − (0) |
| AC133 | CD133 | + (100) | + (100) | + (86) | + (88) | +/− (72) | + (89) |
| OX40 | CD134 | − (0) | − (0) | − (8) | − (6) | − (0) | − (0) |
| SLAMF1 | CD150 | − (0) | − (0) | − (3) | − (0) | − (0) | − (0) |
| BST1 | CD157 | + (90) | + (90) | + (85) | + (74) | + (100) | + (100) |
| CXCR4 | CD184 | + (68) | + (55) | + (75) | + (72) | + (82) | + (82) |
| E-NPP3 | CD203c | − (0) | − (0) | − (0) | − (0) | − (11) | − (0) |
| MDR1 | CD243 | − (10) | − (0) | − (6) | − (10) | − (3) | − (7) |
| OX40L | CD252 | − (0) | − (0) | − (0) | − (0) | −/+ (33) | −/+ (33) |
| CLL-1 | CD371 | + (100) | − (0) | + (92) | + (68) | + (67) | − (17) |
Expression of surface antigens on CD34+/CD38−and CD34+/CD38+ BM stem and progenitor cells was examined by multicolor flow cytometry. All leukemic samples were obtained at diagnosis (AML: ≥7 cases per marker tested; CML: ≥6 cases per marker tested). Control samples (normal BM; ≥5 cases per marker tested) included purchased CD34+ BM cell subsets and BM cells obtained from cases with suspected hematologic neoplasm without persistent cytopenia. Results show the levels of expression of surface markers (as per the score defined below) and as the percentage of positive cases in each group (in parentheses). Score of antibody reactivity: +, clear expression in majority of cases; +/−, weak expression in majority of cases; −/+, expression in minority of cases; −, no expression in a vast majority of cases.
BST1, BM stromal cell antigen 1; DPPIV, dipeptidyl peptidase IV; E-NPP3, ectonucleotide pyrophosphatase/phosphodiesterase 3; LCA, leukocyte common antigen; MDR1, multidrug resistance gene 1; n.c., not yet clustered; OX40L, OX40 ligand; Thy1, thymocyte antigen 1.